MY RESEARCH LAB

Manhattan Behavioral Medicine

I'm proud to lead a team of 10 talented women who serve as clinical research coordinators and physicians. Together, we are dedicated to developing and exploring novel treatments for mental health conditions such as depression, anxiety, and ADHD, as well as more complex conditions such as dementia and autism.

My lab is the first lab to study High-functioning conditions, such as high-functioning depression, ADHD, anxiety, PTSD, bipolar disorder, schizophrenia, postpartum depression and OCD.  We have developed original psychometric scales for mood and anxiety, as well as wellness scales to test products so that they are evidence-based.

Our lab is equipped with cutting-edge technology and state-of-the-art equipment to ensure the highest level of accuracy and efficiency in our research. We are passionate about what we do, and we are constantly seeking new ways to advance the field of mental health treatment.

CLINICAL RESEARCH INVOLVEMENT

  • Phase 3A study to evaluate a drug (dasotraline) on the safety, effectiveness and how well the body tolerates it, in adults with moderate to severe binge eating disorder. Learn more.

    OLE This is a Phase 3, 12 month, multicenter, open-label, flexibly-dosed, safety study in adults with Binge Eating Disorder. Learn more.

    The specific aim of this study is to examine the efficacy and safety of lisdexamfetamine compared with placebo in outpatients with binge eating disorder. Learn more.

  • Acadia Harmony study open label study with Pimavanserin in Dementia with psychosis. Learn more.

    Study with AZTherapies for Mild cognitive Impairment. Learn more.

    Axsome Therapeutics Dementia with Agitation. Learn more.

    EIP Mild cognitive impairment. Learn more.

    Neurim Mild Cognitive Impairment Study. Learn more.

    Suven moderate Dementia Study. Learn more.

    Axovant Moderate Dementia Study. Learn more.

    Axovant open label Moderate dementia study. Learn more.

    Avanir Dementia with agitation study. Learn more.

    Avanir Dementia with agitation open label study. Learn more.

  • Phase 3 age 18-55 Adult double blind placebo controlled ADHD. Learn more.

    Phase 3 age 18-55 open label adult ADHD. Learn more.

    Phase 4 adult study. Learn more.

  • Phase 3 age 12-17 double blind placebo controlled pediatric ADHD. Learn more.

    Phase 3 age 6-11 double blind placebo controlled pediatric ADHD. Learn more.

    Phase 3 open label pediatric ADHD. Learn more.

    Phase 3 age 4-5 open label. Learn more.

    Phase 3 age 4-5 double blind pre-school ADHD. Learn more.

  • Phase 3 Pediatric depression 7-17. Learn more.

    Phase 3 pediatric depression 12-17. Learn more.

    Phase 3 Pediatric depression 7-11. Learn more.

    Phase 3 pediatric depression 12-17. Learn more.

  • Phase 3 pediatric schizophrenia 13-17. Learn more.

    Phase 3 pediatric schizophrenia 13-17. Learn more.

    Phase 3 pediatric schizophrenia 13-17 open label. Learn more.

    Phase 3 pediatric schizophrenia 13-17. Learn more.

  • Phase 3 pediatric GAD. Learn more.

  • Phase 3 pediatric bipolar 10-17. Learn more.

  • Phase 3 pediatric Tourette age 6-17. Learn more.

  • Phase 3 This study will evaluate the efficacy, safety, and tolerability of rapastinel 450 milligrams (mg) compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT. Learn more.

    Phase 3 The study will evaluate the efficacy and safety of ITI-007 in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode. Learn more.

    Phase 3 PostPartum depression Study This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety and pharmacokinetics of SAGE-217 in approximately 140 adult female subjects diagnosed with severe postpartum depression. Learn more.

    Phase 3 The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo. Learn more.

    1289-0049 (2019 – 2020) Schizophrenia

    A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 28-week treatment period as adjunctive therapy to antipsychotic treatment for the prevention of relapse in patients with schizophrenia.

    NYX-783-2004 (2019 – 2020) PTSD

    A Study to Evaluate the Safety and Efficacy of NYX-783 in Subjects with Post-Traumatic Stress Disorder Phase 2

    OTSUKA 331-201-0072 (2019 – 2020) PTSD

    A Phase 3, Multicenter, Randomized, Double-blind Trial of Fixed-Dose Brexpiprazole as Combination Therapy with Sertraline in the Treatment of Adults with Post-traumatic Stress Disorder

    OTSUKA 331-201-00195/242 (2019 – 2020) Borderline Personality Disorder

    A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder